Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It?
INTRODUCTION: The aim of this study was to investigate the effects of imatinib mesylate on platelet aggregation and adenosine triphosphate (ATP) release in chronic myeloid leukemia patients. METHODS: Platelet aggregation and ATP release induced by 5.0 mM adenosine diphosphate, 0.5 mM arachidonic aci...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2016-05-01
|
| Series: | Turkish Journal of Hematology |
| Subjects: | |
| Online Access: | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-03789 |
| _version_ | 1797916889059426304 |
|---|---|
| author | Olga Meltem Akay Fezan Şahin Mutlu Zafer Gülbaş |
| author_facet | Olga Meltem Akay Fezan Şahin Mutlu Zafer Gülbaş |
| author_sort | Olga Meltem Akay |
| collection | DOAJ |
| description | INTRODUCTION: The aim of this study was to investigate the effects of imatinib mesylate on platelet aggregation and adenosine triphosphate (ATP) release in chronic myeloid leukemia patients. METHODS: Platelet aggregation and ATP release induced by 5.0 mM adenosine diphosphate, 0.5 mM arachidonic acid, 1.0 mg/ mL ristocetin, and 2 μg/mL collagen were studied by whole blood platelet lumi-aggregometer in 20 newly diagnosed chronic myeloid leukemia patients before and after imatinib mesylate treatment. RESULTS: At the time of diagnosis, 17/20 patients had abnormal platelet aggregation results; 8 (40%) had hypoactivity, 6 (30%) had hyperactivity, and 3 (15%) had mixed hypo- and hyperactivity. Repeat platelet aggregation studies were performed after a mean of 19 months (min: 5 months-max: 35 months) in all patients who received imatinib mesylate during this period. After therapy, 18/20 (90%) patients had abnormal laboratory results; 12 (60%) had hypoactive platelets, 4 (20%) had mixed hypo- and hyperactive platelets, and 2 (10%) had hyperactive platelets. Three of the 8 patients with initial hypoactivity remained hypoactive, while 2 developed a mixed picture, 2 became hyperactive, and 1 normalized. Of the 6 patients with initial hyperactivity, 4 became hypoactive and 2 developed a mixed pattern. All of the 3 patients with initial hypo- and hyperactivity became hypoactive. Finally, 2 of the 3 patients with initial normal platelets became hypoactive while 1 remained normal. There was a significant decrease in ristocetin-induced platelet aggregation after therapy (p<0.001), while platelet aggregation and secretion induced by other agonists showed no difference after treatment (p>0.05). DISCUSSION AND CONCLUSION: These findings indicate that a significant proportion of chronic myeloid leukemia patients have different patterns of platelet function abnormalities and imatinib mesylate has no effect on these abnormalities, with a significant impairment in ristocetin-induced platelet aggregation. |
| first_indexed | 2024-04-10T13:04:28Z |
| format | Article |
| id | doaj.art-0b2073657dc84516a1a87b5757da779b |
| institution | Directory Open Access Journal |
| issn | 1308-5263 |
| language | English |
| last_indexed | 2024-04-10T13:04:28Z |
| publishDate | 2016-05-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | Turkish Journal of Hematology |
| spelling | doaj.art-0b2073657dc84516a1a87b5757da779b2023-02-15T16:13:00ZengGalenos Publishing HouseTurkish Journal of Hematology1308-52632016-05-0133212713010.4274/tjh.2014.0213TJH-03789Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It?Olga Meltem Akay0Fezan Şahin Mutlu1Zafer Gülbaş2Department Of Hematology, Eskisehir Osmangazi University Medical School, Eskisehir, TurkeyDepartment Of Hematology, Eskisehir Osmangazi University Medical School, Eskisehir, TurkeyDepartment Of Hematology, Eskisehir Osmangazi University Medical School, Eskisehir, TurkeyINTRODUCTION: The aim of this study was to investigate the effects of imatinib mesylate on platelet aggregation and adenosine triphosphate (ATP) release in chronic myeloid leukemia patients. METHODS: Platelet aggregation and ATP release induced by 5.0 mM adenosine diphosphate, 0.5 mM arachidonic acid, 1.0 mg/ mL ristocetin, and 2 μg/mL collagen were studied by whole blood platelet lumi-aggregometer in 20 newly diagnosed chronic myeloid leukemia patients before and after imatinib mesylate treatment. RESULTS: At the time of diagnosis, 17/20 patients had abnormal platelet aggregation results; 8 (40%) had hypoactivity, 6 (30%) had hyperactivity, and 3 (15%) had mixed hypo- and hyperactivity. Repeat platelet aggregation studies were performed after a mean of 19 months (min: 5 months-max: 35 months) in all patients who received imatinib mesylate during this period. After therapy, 18/20 (90%) patients had abnormal laboratory results; 12 (60%) had hypoactive platelets, 4 (20%) had mixed hypo- and hyperactive platelets, and 2 (10%) had hyperactive platelets. Three of the 8 patients with initial hypoactivity remained hypoactive, while 2 developed a mixed picture, 2 became hyperactive, and 1 normalized. Of the 6 patients with initial hyperactivity, 4 became hypoactive and 2 developed a mixed pattern. All of the 3 patients with initial hypo- and hyperactivity became hypoactive. Finally, 2 of the 3 patients with initial normal platelets became hypoactive while 1 remained normal. There was a significant decrease in ristocetin-induced platelet aggregation after therapy (p<0.001), while platelet aggregation and secretion induced by other agonists showed no difference after treatment (p>0.05). DISCUSSION AND CONCLUSION: These findings indicate that a significant proportion of chronic myeloid leukemia patients have different patterns of platelet function abnormalities and imatinib mesylate has no effect on these abnormalities, with a significant impairment in ristocetin-induced platelet aggregation.https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-03789platelet aggregationchronic myeloid leukemiaimatinib mesylate |
| spellingShingle | Olga Meltem Akay Fezan Şahin Mutlu Zafer Gülbaş Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It? Turkish Journal of Hematology platelet aggregation chronic myeloid leukemia imatinib mesylate |
| title | Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It? |
| title_full | Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It? |
| title_fullStr | Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It? |
| title_full_unstemmed | Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It? |
| title_short | Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It? |
| title_sort | platelet dysfunction in patients with chronic myeloid leukemia does imatinib mesylate improve it |
| topic | platelet aggregation chronic myeloid leukemia imatinib mesylate |
| url | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-03789 |
| work_keys_str_mv | AT olgameltemakay plateletdysfunctioninpatientswithchronicmyeloidleukemiadoesimatinibmesylateimproveit AT fezansahinmutlu plateletdysfunctioninpatientswithchronicmyeloidleukemiadoesimatinibmesylateimproveit AT zafergulbas plateletdysfunctioninpatientswithchronicmyeloidleukemiadoesimatinibmesylateimproveit |